Publication: Cost-utility analysis of home-based care for treatment of Thai hemophilia A and B
Issued Date
2014-01-01
Resource Type
ISSN
22121099
Other identifier(s)
2-s2.0-84899825983
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Value in Health Regional Issues. Vol.3, No.1 (2014), 73-78
Suggested Citation
Oraluck Pattanaprateep, Ampaiwan Chuansumrit, Ronnachai Kongsakon Cost-utility analysis of home-based care for treatment of Thai hemophilia A and B. Value in Health Regional Issues. Vol.3, No.1 (2014), 73-78. doi:10.1016/j.vhri.2014.02.008 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/33806
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cost-utility analysis of home-based care for treatment of Thai hemophilia A and B
Other Contributor(s)
Abstract
Objective: This study aimed to evaluate the cost-utility of the home-based care policy versus the no home-based care policy of factor VIII and factor IX concentrate in Thai patients with hemophilia A and B who had no inhibitor or less than 5 Bethesda units. Methods: A Markov model was used to evaluate the cost utility of the two policies. The first policy was "no home-based care" in which patients were treated with blood components only when admitted at the hospital but without home treatment. The second policy was "home-based care" in which factors were prescribed and infused for treatment of early bleeding episodes at home. Input parameters related to clinical and cost were obtained from primary data collection at the National Health Security Office, while patients' quality of life was surveyed from mailed questionnaires. Both costs and health outcomes were discounted at 3%. One-way analysis and probabilistic sensitivity analysis were performed to assess uncertainty surrounding model parameters. Results: Based on governmental perspective, the "home-based care" policy had cost saving in patients with moderate and severe hemophilia when compared with the "no home-based care" policy; in patients with mild hemophilia, the incremental cost-effectiveness ratio was 80,542 Thailand baht (THB) or US $2,684.73 (US $1 = 30 THB). Conclusions: At the ceiling threshold of one time of gross domestic product per capita (120,000 THB per quality-adjusted life-year gained), the "home-based care" policy was cost-effective when compared with the "no home-based care" policy. © 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).